|Title / Titel||Collaborative HIV and Anti-HIV Drug Resistance Network - CHAIN|
|Abstract (PDF, 14 KB)|
|Summary / Zusammenfassung||Anti-HIV drug resistance still represents a threat to the effective use of HIV therapy in the developed and resource-poor regions of the world. Although the availability of triple-regimens has dramatically reduced HIV-related mortality and morbidity, we have seen an emergence of HIV resistance in patients receiving Highly Active Anti-Retroviral Therapy (HAART), associated with increasing rates in disease progression. If we do not respond now with a powerful and decisive effort to counter the threat of anti-HIV drug resistance, we will loose the progress we have made in the last decades in the combat against HIV and will be faced with excess morbidity and mortality, particularly in resource-poor environments, which is associated with increasing costs of clinical, laboratory and therapeutic management of HIV resistance and HIV-infected patients.
For these reasons Europe needs to combine its strengths in HIV and anti-HIV drug resistance research as suggested by the call text. Only through large-scale and durable collaboration between the main actors in the field of HIV and HIV drug resistance we can tackle the main issues preventing us from effectively and durably combating the further emergence and spread of HIV and HIV drug resistance. This large scale integrating project aims to fulfil this need.
Need for an integrated, pan-European translational approach in HIV anti-drug resistance. Whilst Europe harbours world leading experts in various European centres of excellence, active in epidemiological, clinical and/or basic research in HIV and/or HIV resistance in Europe and the developing world, the current European research landscape in HIV and HIV drug resistance is too fragmented to effectively and durably contribute to decreasing the emergence and spread in anti-HIV resistance. New insights in the prevalence and transmission of HIV resistant strains in Europe in various cohort studies and the basic underlying mechanisms causing resistance and their implications for novel antiviral drugs are developed in different networks. As opposed to the current ad hoc collaboration and exchange of knowledge and personnel between these centres of excellence and networks, the next crucial step in the combat against HIV and HIV resistance is to achieve a structural integration of these efforts and knowledge between the centres of excellence on a pan-European scale. Only through a powerful pooling of knowledge, resources, tools and standards and a coordinated spread of excellence can decisive steps towards a durable solution towards the problem of anti-HIV resistance can be achieved. This integrated project aims to fulfil this need. The consortium harbours prominent institutes and researchers representing the state of the art in the broad arena of HIV resistance research and molecular epidemiology research, from experts on the basic research into novel HIV drugs to the coordinators of the major HIV cohort networks in Europe, the WHO and leading clinicians from Eastern Europe and Africa.
There is a strong synergy between the -in many cases funded by FP6 as Coordinated Actions- cohort networks and [acronym]. The aim of [acronym] is to provide the underlying research to underpin the activities of the cohort networks.
For the first time, clinical and virological data from European and African cohorts of adults and children can be merged to address questions hitherto unanswerable due to limited datasets of linked resistance and clinical outcome information.
Together these institutes and their researchers combine the ambition, the knowledge, the resources and the managerial experience necessary to effectively develop and implement sustainable solutions to the main causes underlying the problem of HIV anti drug resistance. It is our firm conviction that in joining our forces on this scale and scope for the first time in history, we are capable of providing Europe and the world with an effective response to the challenges that are in front of us in the combat against HIV resistance.
Mission and associated challenges
The overall joint mission of the consortium is: TO EFFECTIVELY AND DURABLY COMBAT NEW AND EXISTING ANTI-HIV DRUG RESISTANCE IN CLINICAL SETTINGS, WITH SPECIAL EMPHASIS ON EASTERN EUROPE AND IN HEAVILY AFFECTED RESOURCE-POOR REGIONS IN AFRICA.
|Keywords / Suchbegriffe||HIV, drug resistance, europe, treatment failure, mechanisms of resistance, adherence, antiretroviral drugs|
|Project leadership and contacts /
Projektleitung und Kontakte
|Funding source(s) /
FP 7 "Large Scale Integrating Project"
|In collaboration with /
In Zusammenarbeit mit
|Duration of Project / Projektdauer||Jan 2009 to Mar 2014|